Following recent patent expirations of originator biologics, their more affordable biosimilar versions became available. Switching patients from originator to its biosimilar as part of routine clinical practice may result in significant public and private drug...
In our effort to make prescription drug use safer we at the TI are constantly on the alert for what is happening in the wider BC health system. While patients are often told to “take charge...
In Therapeutics Letter 136, just published last week, we ask a question some might find provocative: "How do YOU respond to Conflicts of Interest?" In professional education sessions, we might all be accustomed to the standard...
Statins and a Patient’s Perspective on Informed Decision-making Occasionally people read our Therapeutics Letters and contact us to share their experiences. These anecdotes are not systematically-reviewed evidence, but they sometimes give us insight to the dynamics...